Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Arthritis, Psoriatic;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid;Colitis, Ulcerative;Crohn Disease;Hidradenitis Suppurativa;Psoriasis;Spondylitis, Ankylosing;Uveitis | Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Arthritis, Psoriatic;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid;Colitis, Ulcerative;Crohn Disease;Hidradenitis Suppurativa;Psoriasis;Spondylitis, Ankylosing;Uveitis, Date of authorisation: 15/11/2021, Revision: 1, Status: Authorised | | |